Literature DB >> 16480597

Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma.

Mun-Hon Ng1, Kwok-Hung Chan, Sze-Park Ng, Yong-Sheng Zong.   

Abstract

Nasopharyngeal carcinoma (NPC) is a common cancer among Chinese, especially Southern Chinese; except for a few other ethnic groups with moderate incidence, it is otherwise a rare cancer in the world. NPC has a male dominance of about 3:1 and mainly afflicts people in mid-life. There is now compelling evidences to suggest that Epstein-Barr virus (EBV), a category I human tumor virus defined by UICC (International Agency for Research on Cancer) in 1997, is a causal agent of NPC and is most likely to be involved in the multi-step and multi-factorial development of NPC. In this article, the role of EBV in pathogenesis of NPC is reviewed briefly, and principle applications of EBV antibodies and EBV DNA as markers of NPC are outlined. Based on current knowledge of EBV antibody responses by NPC and taking available testing technologies into account, serologic screening strategy to facilitate efficient early detection of NPC is formulated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480597

Source DB:  PubMed          Journal:  Ai Zheng


  10 in total

1.  Epstein-Barr Virus EA-IgA, VCA-IgA, and EBVNA-IgG Antibodies in a Population of Wuhan, China.

Authors:  Zhen-Gang Tang; Hui-Hui Li; Yun-Cheng Li; Mei-Xia Lv; Xin Xu; Jun-Chao Zeng; Wei-Jia Kong; Rui Yang
Journal:  Curr Med Sci       Date:  2020-03-13

2.  Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.

Authors:  E K Hoebe; S H Hutajulu; J van Beek; S J Stevens; D K Paramita; A E Greijer; J M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2010-12-01

3.  Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma.

Authors:  Dewi K Paramita; Jajah Fachiroh; Sofia M Haryana; Jaap M Middeldorp
Journal:  Clin Vaccine Immunol       Date:  2009-03-25

4.  Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.

Authors:  Junying Guo; Zhaolei Cui; Yuhong Zheng; Xiaoli Li; Yan Chen
Journal:  Pathol Oncol Res       Date:  2020-03-28       Impact factor: 3.201

5.  Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening.

Authors:  J Fachiroh; P R Prasetyanti; D K Paramita; A T Prasetyawati; D W Anggrahini; S M Haryana; J M Middeldorp
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

6.  Fluctuations of epstein-barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up.

Authors:  Su-Mei Cao; Zhiwei Liu; Wei-Hua Jia; Qi-Hong Huang; Qing Liu; Xiang Guo; Teng-Bo Huang; Weimin Ye; Ming-Huang Hong
Journal:  PLoS One       Date:  2011-04-22       Impact factor: 3.240

7.  Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination.

Authors:  Ming-fang Ji; Yuan-long Yu; Wei-ming Cheng; Yong-sheng Zong; Park Sze-park Ng; Daniel Tsin-tien Chua; Mun-hon Ng
Journal:  Chin J Cancer       Date:  2011-02

8.  Clinical values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.

Authors:  Ai-Di Gu; Li-Xia Lu; Yan-Bo Xie; Li-Zhen Chen; Qi-Sheng Feng; Tiebang Kang; Wei-Hua Jia; Yi-Xin Zeng
Journal:  J Transl Med       Date:  2009-08-23       Impact factor: 5.531

9.  Meta-analysis of nasopharyngeal carcinoma microarray data explores mechanism of EBV-regulated neoplastic transformation.

Authors:  Xia Chen; Shuang Liang; WenLing Zheng; ZhiJun Liao; Tao Shang; WenLi Ma
Journal:  BMC Genomics       Date:  2008-07-07       Impact factor: 3.969

10.  Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.

Authors:  Zlata Novalić; Sandra A W M Verkuijlen; Mariska Verlaan; Jos L H Eersels; Inge de Greeuw; Carla F M Molthoff; Jaap M Middeldorp; Astrid E Greijer
Journal:  J Med Virol       Date:  2017-08-29       Impact factor: 2.327

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.